Poly (ADP-Ribose) polymerase inhibitors (PARPI): Associated thrombosis in patients with ovarian cancer

被引：0

作者：

Sanchez Canovas, M. ^{[1
]}

Lopez Robles, J. ^{[1
]}

Garcia Verdejo, F. J. ^{[2
]}

Cacho Lavin, D. ^{[3
]}

Guirao, S. ^{[4
]}

Garrido Fernandez, A. ^{[5
]}

Coma Salvans, E. ^{[6
]}

Quintanar Verduguez, T. ^{[7
]}

Salvador Coloma, C. ^{[8
]}

Fernandez Garay, D. ^{[9
]}

Cumplido, J. D. ^{[10
]}

Ferrer Perez, A. I. ^{[11
]}

Carbo Bague, A. ^{[12
]}

Teigell Munoz, F. J. ^{[13
]}

Munoz Martin, A. J. ^{[14
]}

机构：

[1] Hosp Gen Univ Morales Meseguer, Med Oncol Dept, Murcia, Spain

[2] Hosp Univ Jaen, Med Oncol Dept, Jaen, Spain

[3] HUMV Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain

[4] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[5] Hosp Univ Alvaro Cunqueiro, Med Oncol Dept, Pontevedra, Spain

[6] Hosp Duran & Reynals, ICO Inst Catala Oncol lHospitalet, Med Oncol Dept, Lhospitalet De Llobregat, Spain

[7] Hosp Gen Univ Elche, Med Oncol Dept, Alicante, Spain

[8] Hosp Lluis Alcanyis Xativa, Med Oncol Dept, Valencia, Spain

[9] Hosp Costa del Sol, Agencia Sanitaria Costa del Sol, Med Oncol Dept, Marbella, Spain

[10] Hosp Univ Torrevieja, Med Oncol Dept, Torrevieja, Spain

[11] Obispo Polanco Hosp, Med Oncol Dept, Teruel, Spain

[12] ICO Girona Inst Catala Oncol Girona, Med Oncol Dept, Girona, Spain

[13] Hosp Univ Infanta Cristina, Internal Med Dept, Parla, Spain

[14] Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1955

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1861P

引用

页码：S1095 / S1095

页数：1

共 50 条

[21] COST COMPARISON OF ADVERSE EVENT MANAGEMENT WITH POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS (PARPI) IN THE MAINTENANCE TREATMENT OF ADVANCED OVARIAN CANCER
Hettle, R.
McLaurin, K.
Mihai, A.
Poeton, A.
Muston, D.
Lopez-Acevedo, M.
Maguire, P.
Wynne, T.
VALUE IN HEALTH, 2020, 23 : S42 - S42
[22] Who is first in line? Trends in use of poly (ADP-ribose) polymerase inhibitors (PARPi) among commercially insured women with ovarian cancer
Dottino, Joseph
Argetsinger, Stephanie
Costa, Rebecca
Esselen, Katharine
Ross-Degnan, Dennis
Wagner, Anita
GYNECOLOGIC ONCOLOGY, 2023, 176 : S221 - S221
[23] Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics
He, Jin-xue
Yang, Chun-hao
Miao, Ze-hong
ACTA PHARMACOLOGICA SINICA, 2010, 31 (09) : 1172 - 1180
[24] Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics
Jin-xue He
Chun-hao Yang
Ze-hong Miao
Acta Pharmacologica Sinica, 2010, 31 : 1172 - 1180
[25] Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer
Rescigno, Pasquale
Chandler, Robert
de Bono, Johann
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2018, 12 (03) : 339 - 343
[26] Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer
Broenimann, Stephan
Lemberger, Ursula
Bruchbacher, Andreas
Shariat, Shahrokh F.
Hassler, Melanie R.
CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 519 - 526
[27] Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer
Lewis, Cristina
Low, Jennifer A.
CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (12) : 1051 - 1056
[28] A guide to poly ADP-ribose polymerase inhibitor (PARPi) toxicity management
Patel, Shrina Divyesh
Joseph, Donyika Ann
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (07) : 916 - 916
[29] Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
Vanacker, Helene
Romeo, Clemence
Ray-Coquard, Isabelle
CURRENT OPINION IN ONCOLOGY, 2019, 31 (05) : 394 - 403
[30] Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer
Ratner, Elena S.
Sartorelli, Alan C.
Lin, Z. Ping
CURRENT OPINION IN ONCOLOGY, 2012, 24 (05) : 564 - 571

← 1 2 3 4 5 →